|Bid||0.00 x 900|
|Ask||0.00 x 1200|
|Day's Range||45.43 - 46.10|
|52 Week Range||34.64 - 49.50|
|Beta (3Y Monthly)||1.16|
|PE Ratio (TTM)||882.12|
|Earnings Date||Feb 26, 2020 - Mar 2, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||55.43|
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]
PARSIPPANY, N.J., Nov. 26, 2019 -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will present at the 31st Annual Piper Jaffray Healthcare Conference at 9:30 AM.
PARSIPPANY, N.J., Nov. 13, 2019 -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will present at the Jefferies 2019 London Healthcare Conference at 2:40 PM GMT.
Pacira's (PCRX) third-quarter results reflect an earnings beat while revenues almost match estimates. Exparel drives year-over-year growth.
Pacira (PCRX) delivered earnings and revenue surprises of 41.18% and -0.33%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
-- Total revenues increased 25 percent over prior year to $104.7 million in third quarter -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., Nov. 07, 2019 --.
Pacira (PCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacira BioSciences, Inc. (PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Thursday, November 7, 2019. International callers may dial 1-720-545-0035 and use the same passcode.
We think intelligent long term investing is the way to go. But along the way some stocks are going to perform badly...
NEW YORK , Sept. 24, 2019 /PRNewswire/ -- Pacira BioSciences Inc. (NASD: PCRX) will replace Shutterfly Inc. (NASD: SFLY) in the S&P SmallCap 600 effective prior to the open of trading on Monday, September ...
Pacira BioSciences, Inc. (PCRX), a leading provider of innovative non-opioid pain management options, today announced the appointment of Christopher J. Christie to its board of directors. Chris Christie served as the 55th Governor of the State of New Jersey from January 2010 to January 2018. “We are honored to welcome Governor Christie to the Pacira board of directors.
The company intends that these study results will provide the foundation for a supplemental New Drug Application submission to the U.S. Food and Drug Administration (FDA) seeking expansion of the EXPAREL label to include children aged six and over. “Pediatric patients—arguably our most vulnerable surgical population—urgently need opioid-free options to manage postsurgical pain. This is particularly true for children six to 12 years of age who do not have any FDA-approved local anesthetic options today,” said Dave Stack, chairman and chief executive officer of Pacira.
CEO and Chairman of Pacira Biosciences Inc (30-Year Financial, Insider Trades) David M Stack (insider trades) sold 12,849 shares of PCRX on 08/15/2019 at an average price of $39.15 a share. Continue reading...